NCT03689595 Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
| NCT ID | NCT03689595 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 30,000 participants |
| Start Date | 2018-10-31 |
| Primary Completion | 2033-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30,000 participants in total. It began in 2018-10-31 with a primary completion date of 2033-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 30 years * AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer. * Those over 18 are also eligible if they have 2 or more family members with a blood cancer Exclusion Criteria: \* • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy. • Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia First-degree relatives would not need to be identified by the participant. This study includes all special populations who fall within the eligible high-risk age range, ≥ 30 years of age, including adults unable to consent, pregnant women, and prisoners. These populations will not be excluded as this is a non-therapeutic study.
Contact & Investigator
Irene Ghobrial, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT03689595 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03689595 currently recruiting?
Yes, NCT03689595 is actively recruiting participants. Contact the research team at promisestudy@partners.org for enrollment information.
Where is the NCT03689595 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT03689595 clinical trial?
NCT03689595 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Irene Ghobrial, MD at Dana-Farber Cancer Institute. The trial plans to enroll 30,000 participants.